DROLOXIFENE, A NEW ANTIESTROGEN IN POSTMENOPAUSAL ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS OF A DOUBLE-BLIND DOSE-FINDING PHASE-II TRIAL

被引:56
|
作者
BRUNING, PF
机构
关键词
D O I
10.1016/0959-8049(92)90530-F
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Droloxifene (3-OH-tamoxifen citrate) is a novel anti-oestrogen with a higher affinity for oestrogen receptors (ER), a lower oestrogenic to anti-oestrogenic activity ratio and faster pharmacokinetics compared with tamoxifen. From May 1988 to April 1991, 369 postmenopausal women with metastatid or locally unresectable breast cancer of which the ER or progesterone receptor status was positive or unknown, were randomised to receive an oral dose of 20, 40 or 100 mg droloxifene once daily. 43 Brazilian, Canadian and European centres took part in this double-blind phase II trial. 60 women were ineligible for violation of entry criteria; 20 were inevaluable and 15 still await definitive response evaluation. 234 patients have been evaluated for response. The over-all objective response rate (complete plus partial) was 92/234 (39.3%): 23/74 (31.1%) for 20 mg, 33/74 (44.6%) for 40 mg and 36/86 (41.9%) for 100 mg (not significantly different within this dose range). There was no significant difference in time to tumour progression between the three doses. Toxicity was minimal at all doses. These preliminary results show that droloxifene is active against advanced breast cancer. Because of its outstanding preclinical characteristics, the drug warrants large-scale clinical investigation.
引用
收藏
页码:1404 / 1407
页数:4
相关论文
共 50 条
  • [1] TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER WITH DROLOXIFENE - RESULT OF A PHASE-II DOUBLE-BLIND DOSE-FINDING TRIAL
    CHEVALLIER, B
    SPIELMANN, M
    MARTY, M
    SERIN, D
    POUILLART, P
    HULIN, MT
    MIGNOT, L
    LAURAINE, EP
    KRAMS, M
    MERTENS, H
    RAUSCHNING, W
    [J]. BULLETIN DU CANCER, 1993, 80 (07) : 624 - 628
  • [2] DROLOXIFENE, A NEW ANTIESTROGEN, IN ADVANCED BREAST-CANCER - A DOUBLE-BLIND DOSE-FINDING STUDY
    DESCHENES, L
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 : S52 - S55
  • [3] EUROPEAN EARLY PHASE-II DOSE-FINDING STUDY OF DROLOXIFENE IN ADVANCED BREAST-CANCER
    BELLMUNT, J
    SOLE, L
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 : S36 - S39
  • [4] DROLOXIFENE - A NEW ANTIESTROGEN - A PHASE-II STUDY IN ADVANCED BREAST-CANCER
    HAARSTAD, H
    GUNDERSEN, S
    WIST, E
    RAABE, N
    MELLA, O
    KVINNSLAND, S
    [J]. ACTA ONCOLOGICA, 1992, 31 (04) : 425 - 428
  • [5] JAPANESE EARLY PHASE-II STUDY OF DROLOXIFENE IN THE TREATMENT OF ADVANCED BREAST-CANCER - PRELIMINARY DOSE-FINDING STUDY
    ABE, O
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 : S40 - S45
  • [6] DROLOXIFENE IN POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER - DOUBLE-BLIND RANDOMIZED PHASE-II STUDY
    MARSCHNER, N
    KREIENBERG, R
    BALAS, R
    BRANDTNER, M
    SCHLINGENSIEPEN, R
    SCHUMANN, S
    BUTTNER, S
    STAAB, HJ
    RAUSCHNING, W
    [J]. ONKOLOGIE, 1994, 17 : 32 - 39
  • [7] PHASE-II STUDY OF CARBOPLATIN IN ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS
    MARTIN, M
    DIAZRUBIO, E
    CASADO, A
    VEGA, JML
    [J]. SEMINARS IN ONCOLOGY, 1991, 18 (01) : 23 - 27
  • [8] PRELIMINARY-RESULTS OF A PHASE-II TRIAL OF CHRONIC ORAL ETOPOSIDE IN BREAST-CANCER
    MARTIN, M
    CASADO, A
    LLUCH, A
    ADROVER, E
    DIAZRUBIO, E
    GARCIACONDE, J
    [J]. CANCER TREATMENT REVIEWS, 1993, 19 : 47 - 52
  • [9] CHEMOTHERAPY WITH ESTROGENIC RECRUITMENT IN ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS OF A PHASE-II STUDY OF THE EORTC BREAST-CANCER COOPERATIVE GROUP
    VANDERWIJST, JB
    JULIEN, JP
    FERRAZZI, E
    CLARYSSE, A
    HEUSON, JC
    ROTMENSZ, N
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1983, 19 (02): : R4 - R4
  • [10] PHASE-II TRIAL OF TAMOXIFEN IN ADVANCED BREAST-CANCER
    WIGGANS, RG
    WOOLLEY, PV
    SMYTHE, T
    HOTH, D
    MACDONALD, JS
    GREEN, L
    SCHEIN, PS
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1979, 3 (01) : 45 - 48